<DOC>
	<DOCNO>NCT00281619</DOCNO>
	<brief_summary>The purpose study determine fast child , recent kidney transplant , absorb , breakdown eliminate mycophenolic acid ( CellCept ) follow prescribe dose . The result may lead good dose base individual need .</brief_summary>
	<brief_title>PK-PD Study Mycophenolic Acid ( CellCept ) Pediatric Kidney Transplant Patients</brief_title>
	<detailed_description>This open-label , inpatient-outpatient population pharmacokinetic-pharmacodynamic ( PK-PD ) study mycophenolic acid ( MPA ) pediatric subject ( age 2-17 year ) recent kidney transplant , well stable renal transplant period stable oral regimen MPA . The primary objective study develop population pharmacokinetic-pharmacodynamic ( PK-PD ) model mycophenolic acid ( MPA ) mycophenolic acid glucuronide ( MPAG ) order improve individualize pediatric dosing . Subjects receive CellCept part clinical standard care . It anticipate clinical portion study patient approximately six month post renal transplant four study day : screening visit pre-transplant , two 10-hour inpatient day 2-3 6-9 day post-transplant , one ( 10 hour ) outpatient visit 3-6 month post-transplant . Pharmacokinetic pharmacodynamic measurement conduct various time point ( 9 hour post dose ) study day 2 , 3 , 4 . Safety data collect include physical examination , measurement vital sign , laboratory assessment , well data adverse event clinical outcome .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Male subject nonpregnant female subject age 2 17 year receive kidney transplant post transplant MMF contain immunosuppressive therapy . Subjects may enrol 18th year . Minimum weight 11 kg . A signed dated IRB approve parental / guardian inform consent form IRBapproved child assent form applicable . A high probability compliance completion study . For posttransplant study period : Subjects stable kidney allograft least 3 month posttransplant receive regimen MMF ( cyclosporine tacrolimus ) least 30 day study visit ( 36 month posttransplant ) . May clinically important abnormality clinical /or laboratory evaluation abnormality relate underlying condition determine principal investigator . Other variation establish normal range may acceptable clinically significant opinion investigator . Any medical condition ( active chronic ) prior surgery may interfere pharmacokinetic behavior MMF ( absorption , distribution elimination ) determine PI . Active systemic infection . History substance abuse . Signs symptoms active hepatitis ( history hepatitis B C virus infection permit ) . Known history suspect infection human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pediatric Kidney Transplant</keyword>
	<keyword>Kidney Transplant</keyword>
	<keyword>CellCept</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>Mycophenolic Acid</keyword>
	<keyword>MPA</keyword>
</DOC>